Browsing by Author "Chang, Alex"

Now showing 1 - 2 of 2
  • Thumbnail Image
    ItemOpen Access
    Association of a reduction in central obesity and phosphorus intake with changes in urinary albumin excretion: The PREMIER study
    (American Journal of Kidney Diseases, 2013-11-01) Chang, Alex; Batch, Bryan C; McGuire, Heather L; Vollmer, William M; Svetkey, Laura P; Tyson, Crystal C; Sanguankeo, Anawin; Anderson, Cheryl; Houston, Jessica; Appel, Lawrence J
    Background: Excess adiposity and dietary factors may be important determinants of urinary albumin excretion (UAE). Study Design: Observational analysis of PREMIER, a randomized trial designed to lower blood pressure using behavioral interventions (counseling on weight loss, healthy diet, and exercise). Setting & Participants: 481 participants with normal kidney function who provided adequate 24-hour urine collections at baseline and 6 months. Predictors: Change in waist circumference; 24-hour urine sodium, potassium, and phosphorus excretion; and protein intake estimated from urea nitrogen. Outcomes & Measurements: The primary outcome was change in log-transformed 24-hour UAE over 6 months. Results: After 6 months, the proportion of individuals with UAE ≥10 mg/d decreased from 18.7% to 12.7% (P < 0.001). Changes in mean waist circumference (-4.2 ± 6.6 [SD] cm), 24-hour excretion of sodium (-28.2 ± 71.7 mmol/d), potassium (+8.4 ± 27.8 mmol/d), phosphorus (-27.7 ± 314.1 mg/d), and protein intake (-1.7 ± 19.4 g/d) were observed. After adjustment for relevant covariates, the following variables were associated significantly with reduction in ln(UAE) in separate models: decrease in waist circumference (P = 0.001), decrease in 24-hour urine phosphorus excretion (P < 0.001), and decrease in protein intake (P = 0.01). In a multivariable model including these 3 predictors, decreases in waist circumference (P = 0.002) and 24-hour urine phosphorus excretion (P = 0.03), but not change in protein intake (P = 0.5), remained associated significantly with reduction in ln(UAE). These associations remained significant even after adjustment for changes in blood pressure and insulin resistance. Baseline UAE and metabolic syndrome modified the relationship of waist circumference with ln(UAE); specifically, individuals with higher UAE and baseline metabolic syndrome experienced greater reductions in ln(UAE) from decreases in waist circumference. Limitations: Observational study with potential for confounding. Conclusions: In adults with normal kidney function, decreases in waist circumference and 24-hour urine phosphorus excretion are associated with reductions in UAE. These findings support the rationale for clinical trials to determine whether reducing dietary phosphorus intake or waist circumference could prevent chronic kidney disease or slow its progression. © 2013 National Kidney Foundation, Inc.
  • Thumbnail Image
    ItemOpen Access
    Impact of Kidney Function on Effects of the Dietary Approaches to Stop Hypertension (Dash) Diet.
    (J Hypertens (Los Angel)) Tyson, Crystal C; Kuchibhatla, Maragatha; Patel, Uptal D; Pun, Patrick H; Chang, Alex; Nwankwo, Chinazo; Joseph, Michael A; Svetkey, Laura P
    OBJECTIVES: Although the Dietary Approaches to Stop Hypertension (DASH) diet lowers blood pressure in adults with hypertension, how kidney function impacts this effect is not known. We evaluated whether Estimated Glomerular Filtration Rate (eGFR) modifies the effect of the DASH diet on blood pressure, markers of mineral metabolism, and markers of kidney function. METHODS: Secondary analysis of the DASH-Sodium trial, a multicenter, randomized, controlled human feeding study that evaluated the blood pressure lowering effect of the DASH diet at three levels of sodium intake. Data from 92 participants with pre-hypertension or stage 1 hypertension during the 3450 mg /day sodium diet assignment contributed to this analysis. Stored frozen plasma and urine specimens were used to measure kidney related laboratory outcomes. RESULTS: Effects of the DASH diet on blood pressure, phosphorus, intact parathyroid hormone, creatinine, and albuminuria were not modified by baseline eGFR (mean 84.5 ± 18.0 ml/min/1.73 m(2), range 44.1 to 138.6 ml/min/1.73 m(2)) or the presence of chronic kidney disease (N=13%). CONCLUSIONS: The impact of the DASH diet on blood pressure, markers of mineral metabolism, and markers of kidney function does not appear to be modified by eGFR in this small subset of DASH-Sodium trial participants with relatively preserved kidney function. Whether greater reduction in eGFR modifies the effects of DASH on kidney related measures is yet to be determined. A larger study in individuals with more advanced kidney disease is needed to establish the efficacy and safety of the DASH diet in this patient population.